glioblastoma
Overview
Glioblastoma (also called glioblastoma multiforme or GBM) is an aggressive and fast-growing type of brain cancerthat begins in glial cells, which support and protect neurons. It’s the most common malignant primary brain tumor in adults. GBM typically affects the cerebrum, the largest part of the brain, and tends to infiltrate surrounding brain tissue, making it extremely difficult to remove completely. Its rapid growth and location in the brain contribute to severe neurological symptoms and a poor prognosis.
Why It’s Important
Glioblastoma is highly lethal and requires immediate medical attention. Even with surgery, radiation, and chemotherapy, survival rates are low, with most patients surviving only 12 to 18 months after diagnosis. Because it affects essential brain functions—like movement, speech, memory, and behavior—it often leads to a significant loss of independence and quality of life. Early detection and multidisciplinary care can slightly improve outcomes.
Quick Facts
Affects mostly adults aged 45 and older, but can occur at any age
More common in men than women
Accounts for nearly 48% of all malignant brain tumors
Always considered grade IV (most aggressive) by the WHO
Rarely spreads outside the brain or spinal cord
Has a poor prognosis, with a 5-year survival rate under 10%
What Happens in the Body
Glioblastoma originates in the astrocytes, star-shaped glial cells in the brain. The tumor grows rapidly and forms irregular projections that invade healthy brain tissue. It creates new blood vessels to feed its growth (angiogenesis) and often causes swelling (edema) in the brain. This disrupts normal brain function, increases intracranial pressure, and can cause widespread neurological impairment. It rarely metastasizes outside the central nervous system but aggressively spreads within the brain.
Common Signs and Symptoms
Symptoms vary depending on the tumor’s location but may include:
Persistent headaches, often worse in the morning
Nausea and vomiting
Seizures, especially in adults without a history of epilepsy
Cognitive decline, memory loss, or confusion
Speech difficulties or trouble understanding language
Personality changes or mood swings
Weakness or numbness on one side of the body
Vision problems or double vision
Diagnosis
MRI with contrast (preferred imaging method)
CT scan if MRI isn’t available
Biopsy or surgical resection to confirm tumor type and grade
Molecular testing for gene mutations (e.g., IDH, MGMT, EGFR) that can affect prognosis and treatment
See a doctor if:
You experience new or worsening neurological symptoms
You have unexplained seizures, vision issues, or headaches
You’ve had a prior brain tumor or radiation exposure
Treatment and Management
Surgery: Aim is to remove as much of the tumor as possible (debulking)
Radiation therapy: Typically follows surgery to slow tumor regrowth
Chemotherapy: Most commonly temozolomide (Temodar)
Tumor-treating fields (TTF): A wearable device that uses electrical fields to disrupt cancer cell division
Clinical trials: May include immunotherapy, gene therapy, or targeted drugs
Treatment is not curative—it focuses on extending survival and improving quality of life
Risks and Complications
Rapid recurrence even after treatment
Severe cognitive and motor impairments
Depression, anxiety, and personality changes
Swelling of the brain due to tumor or treatment side effects
Shortened lifespan, typically within 1–2 years
Who Is at Risk
Older adults, especially over age 50
Men more than women
People with certain genetic syndromes (e.g., Li-Fraumeni, Turcot syndrome)
Previous radiation therapy to the head
No clear environmental cause in most cases
Related Conditions
Other gliomas (astrocytoma, oligodendroglioma)
Seizure disorders
Hydrocephalus (fluid buildup in the brain)
Brain metastases from other cancers
When to See a Doctor
If you have new or worsening headaches, especially with other neurological symptoms
If you develop sudden seizures
If you or a loved one is experiencing rapid personality or cognitive changes
If you have a family history of brain tumors or genetic cancer syndromes
Last Updated: July 30, 2025

